

AMENDMENTS TO THE CLAIMS

Claim 1 (Cancelled)

Claim 2 (Cancelled)

Claim 3 (Currently Amended): The cell of claim ~~[[1]]~~ 22 wherein said first product is a transactivator of a tetracycline ~~regulated~~ promoter/operator or a fusion protein comprising said transactivator.

Claim 4 (Currently Amended): The cell of claim ~~[[1]]~~ 22 wherein said second ~~nucleic acid construct comprises~~ inducible promoter is a tetracycline ~~regulated~~ promoter/operator.

Claim 5 (Currently Amended): The cell of claim ~~[[1]]~~ 22 wherein said ~~second product~~ viral RNA binding protein is a rev protein.

Claim 6 (Currently Amended): The cell of claim ~~[[1]]~~ 22 wherein said third ~~construct~~ comprises a promoter inducible promoter is derived from a retroviral 5' LTR.

Claim 7 (Currently Amended): ~~A packaging cell comprising a first, second, and third nucleic acid constructs which regulate expression of one or more than one viral envelope or G protein wherein~~

~~said first nucleic acid construct is capable of expressing an encoded first product;~~

~~said first product is capable of regulating expression of a second product encoded on said second nucleic acid construct; and~~

~~said second product is capable of regulating expression of said~~

The cell of claim 22 wherein the viral gene product is a viral envelope protein or a G protein;
~~which is encoded by a sequence present on said third nucleic acid construct.~~

Claim 8 (Original): The cell of claim 7 further comprising an additional nucleic acid construct that encodes retroviral gag and pol proteins.

Claim 9 (Currently Amended): The cell of claim ~~[[1]]~~ 22 wherein said first product is a tat protein or a chimeric protein comprising a tat protein.

Claim 10 (Original): The cell of claim 7 wherein said viral gene product is a G protein.

Claim 11 (Currently Amended): The cell of claim ~~[[1]]~~ 22 which is stably transfected with said nucleic acid constructs.

Claim 12 (Currently Amended): The cell of claim ~~[[1]]~~ 22 further comprising a conditionally replicating viral vector and wherein said cell packages said vector.

Claim 13 (Original): The cell of claim 12 wherein said vector is derived from HIV-1.

Claim 14 (Currently Amended): The cell of claim 13 wherein said ~~G-protein~~ viral gene product is a VSV or Mokola virus G protein.

Claim 15 (Original): A method of packaging a viral vector comprising culturing the cell of claim 13 under conditions wherein said first nucleic acid construct expresses said first product.

Claim 16 (Cancelled)

Claim 17 (Cancelled)

Claim 18 (Currently Amended): The cell of claim ~~[[16]]~~ 7 wherein said ~~second-product~~ viral RNA binding protein is a rev protein.

Claim 19 (Cancelled)

Claim 20 (Currently Amended): The cell of claim [[16]] 7 further comprising a conditionally replicating viral vector and wherein said cell packages said vector.

Claim 21 (Currently Amended): A method of packaging a viral vector comprising culturing the cell of claim [[20]] 23 under conditions wherein said first nucleic acid construct expresses said first product.

Claim 22 (New): A packaging cell comprising:

a first nucleic acid construct comprising a nucleotide sequence encoding a first inducible promoter and a first product, wherein the first inducible promoter regulates expression of first product and the first inducible promoter is selected from the group consisting of a tetracycline promoter/operator, a retroviral long terminal repeat (LTR) and a steroid promoter region;

a second nucleic acid construct comprising a nucleotide sequence encoding a second inducible promoter and a second product, wherein the second inducible promoter is induced by the first product and the second product encodes a viral RNA binding protein; and

a third nucleic acid construct comprising a nucleotide sequence encoding a third inducible promoter and a viral gene product, wherein the third inducible promoter is induced by the second product.

Claim 23 (New): The cell of claim 20, wherein said vector is derived from HIV-1.

Claim 24 (New): The cell of claim 22, wherein said second product encodes rev and said third construct further comprises a nucleotide sequence encoding a rev responsive element (RRE).